Locally or regionally advance squamous cell carcinoma. Patients with Stage III hypopharynx or Stage IV a-b squamous cell carcinoma (other than oropharyngeal) or Stage IV a-b HPV negative oropharyngeal may be eligible. Participants will be treated with Taxotere/Cisplatin and ABT888 followed by Cisplatin and Radiation Therapy. Participants must have measurable disease and be able to swallow.
Exclusions include, but are not limited to: Seizure disorders, impaired gastrointestinal function, HIV (currently on antiviral cocktail), chronic systemic steroid use and unstable angina, cardiac arrhythmia or infection.
Use of IV GC4419 with chemotherapy and radiation for mucositis prevention.
Inclusions include patients with Squamous Cell Carcinoma of the oral cavity or oropharynx who will be starting chemotherapy and radiation with IMRT between 2.0-2.2 Gy per day.
Exclusions include, but are not limited to, tumors of the lips, larynx, hypopharynx, sinuses, salivary glands or an unknown primary, Stage IV C disease, active infection/oral mucositis and HIV or Hep B or C.
“I have an aggressive type of cancer and it was time to take drastic measures…When I heard about the trial from Dr. Hodge, I felt privileged to have this type of care and the chance to help others who may be in my shoes one day.”